|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The presence of autoantibodies against podocyte antigens phospholipase A2 receptor (PLA2R) and thrombospondin type 1 domain containing 7A (THSD7A) in MN suggests an autoimmune mechanism.
|
30538665 |
2018 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The diagnostic performance of the phospholipase A2 receptor (PLA2R) and immunoglobulin G4 (IgG4) detection based on immunohistochemistry were evaluated using biopsy tissues of 59 primary and 56 secondary MGN cases for discrimination between primary MGN and secondary MGN.
|
28362702 |
2018 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We describe a patient diagnosed with anti-phospholipase A2 receptor antibody positive membranous nephropathy and recurrent VTE while on therapeutic dosing of apixaban.
|
30421320 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy.
|
30541581 |
2018 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In membranous nephropathy (MN), which is characterized by deposition of immune complexes along the glomerular basement membrane (GBM), phospholipase A2 receptor (PLA2R) and thrombospondin type 1 domain-containing 7A are target antigens in approximately 70% and 1%-5% of cases of primary MN, respectively.
|
31061139 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-phospholipase A2 receptor antibodies and the pathogenesis of membranous nephropathy.
|
25401774 |
2014 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These include identification of neutral endopeptidase (NEP) as the target antigen in alloimmune MN resulting from fetomaternal immunization in NEP-deficient mothers, and our demonstration that a high proportion of patients with idiopathic MN (IMN) have circulating antibodies to the M-type phospholipase A2 receptor (PLA2R), a transmembrane protein located on podocytes.
|
20182413 |
2010 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A (THSD7A) are the two major autoantigens in primary membranous nephropathy (MN), and define two molecular subclasses of this disease.
|
28674044 |
2017 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Autoantibodies specific for the phospholipase A2 receptor in recurrent and De Novo membranous nephropathy.
|
21827616 |
2011 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The phospholipase A2 receptor (PLA2R1) is the major autoantigen in primary membranous nephropathy.
|
29114041 |
2018 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A highly sensitive time-resolved fluoroimmunoassay (TRFIA) was developed to quantify serum antibodies against the phospholipase A2 receptor (anti-PLA2R-IgG) for differential diagnosis of membranous nephropathy.
|
28397878 |
2017 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A 45-year-old man with membranous nephropathy negative for serum anti-phospholipase-A2-receptor antibody, showed no response to corticosteroids and cyclophosphamide.
|
29924035 |
2018 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The utility of phospholipase A2 receptor autoantibody in membranous nephropathy after kidney transplantation.
|
29988247 |
2018 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A (THSD7A) were identified as pathogenic antigens in patients with membranous nephropathy (MN).
|
31243053 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antibodies against M-Type Phospholipase A2 Receptor May Predict Treatment Response and Outcome in Membranous Nephropathy.
|
30472708 |
2018 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, these findings point out the important role of APLA2R as a tool to predict the disease course and establish personalized therapeutic options at the moment of diagnosis of primary MN.
|
30747150 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Predominant immunoglobulin (Ig) G1 subclass and negative phospholipase-A2 receptor staining, together with granular-positive glomerular capillary co-localization of MPO and IgG staining, suggested secondary MN due to MPO-MPO-ANCA immune-complex.
|
28580649 |
2017 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our understanding of the pathogenesis of primary MN has advanced greatly with the identification of M-type phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A as target antigens whose antibodies serve as biomarkers of this disease.
|
29852477 |
2018 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
While the pathogenesis of MN is still controversial, the detection of autoantibodies against two specific glomerular antigens, phospholipase A2 receptor (PLA<sub>2</sub>R) and thrombospondin type 1 domain containing 7A (THSD7A), together with the beneficial effect of therapies targeting B cells, have highlighted the main role of autoreactive B cells driving this renal disease.
|
31788474 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The M-type phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A (THSD7A) were identified as intrinsic antigens in primary membranous nephropathy (MN).
|
28992353 |
2018 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
While a negative serum anti-phospholipase A2 receptor did not rule out a primary form of MN, it was also uncertain whether positive serologic tests for syphilis could represent a secondary factor.
|
28245485 |
2017 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Renal biopsy confirmed beginning anti-phospholipase A2 receptor antibody membranous nephropathy.
|
30107838 |
2018 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Membranous glomerulopathy (MG) is most commonly caused by autoantibodies directed against the podocyte phospholipase A2 receptor (PLA2R1) and common variants in this gene are associated with MG.
|
25187357 |
2014 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic value of phospholipase A2 receptor in primary membranous nephropathy: a systematic review and meta-analysis.
|
31140029 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
So nephrology has seen real progress in understanding of glomerulonephritis disease mechanisms - not only regarding primary membranous glomerulonephritis (with the recent identification of the phospholipase A2 receptor being the underlying antigen) but also regarding secondary pauci-immune glomerulonephritis due to ANCA-positive vasculitis.
|
22684653 |
2013 |